Stimulating Erythropoiesis: Future Perspectives

Ashraf Mikhail\textsuperscript{a}  Adrian Covic\textsuperscript{c}  David Goldsmith\textsuperscript{b}

\textsuperscript{a}Renal Unit, Morriston Hospital, Swansea, and \textsuperscript{b}Renal Unit, Guy’s Hospital, London, UK; \textsuperscript{c}Parhon Hospital, Iasi, Romania

Key Words
Anaemia \cdot Cytoprotection \cdot Erythropoiesis-stimulating agent \cdot Erythropoietin

Abstract
The introduction of recombinant human erythropoietin (rHuEpo) nearly 20 years ago has revolutionised the management of patients with CKD, providing the opportunity for safe long-term anaemia correction without the attendant risks identified with blood products. Based on our expanding knowledge in this area, there are many exciting and innovative new approaches to anaemia correction that stand on, or are close to, the threshold of yielding products ready for clinical use. Recently, an Epo-related molecule called continuous Epo receptor activator has been licensed in Europe, and other molecules are in various processes of development, including Epo mimetic peptide. The search goes on for orally active antianaeum therapies, and several strategies are being investigated. Furthermore, it is now clear that in addition to the anaemia-correction properties of erythropoiesis-stimulating agents, there is the potential for cytoprotection by prevention of cellular apoptosis. This effect could be used in the prevention of ischaemia-reperfusion injury as well as other conditions associated with acute kidney injury and other disease processes. The aim of this article is to discuss these possible future strategies, focusing in particular on those with a reasonable likelihood of a pharmaceutical product that is likely to be used clinically.
the action of Epo has improved significantly. Based on our expanding knowledge in this area, there are many exciting and innovative new approaches to anaemia correction that stand on or are close to the threshold of yielding products ready for clinical use.

The aim of this article is to introduce the reader to possible potential avenues for future management of anaemia in CKD rather than providing future therapeutic recommendations (table 1). We focus in particular on those mechanisms with a reasonable likelihood of a clinically useful product. In addition, we will discuss different methods by which science is trying to develop strategies and products that may address the limitations of the currently available ESAs.

### Biosimilar Erythropoietin

A generation of biotechnology-derived therapeutic agents are reaching the end of their patent lives, heralding the market entry of biosimilars. Recently, the Committee for Medicinal Products for Human Use has given a favourable opinion of two biosimilar epoetins, alfa (HX575) and zeta, and both are now licensed in the EU. Nevertheless, recombinant proteins are associated with a number of issues which distinguish them from traditional chemical drugs and their generics. Recombinant proteins are highly complex at the molecular level, and biological manufacturing processes are highly elaborate: they involve cloning, selection of a suitable cell line, fermentation, purification, and formulation. In addition, the therapeutic properties of recombinant proteins are highly dependent on each step of the manufacturing process. Since the manufacturing process will be different from that used by the innovator, concerns about the safety, efficacy and consistency of the clinical effects may be a limiting factor in the licensing/marketing of future biosimilar Epos [3]. Of particular concern is the potential immunogenicity of biosimilars. The immunogenicity of therapeutic protein is influenced by several factors such as protein sequence, the presence of exogenous or endogenous epitopes, and the degree to which glycosylation influences the exposure of antigenic sites and their solubility. In addition, immunogenicity is also influenced by formulation and storage, downstream processing, and the level of impurity or presence of contaminants. Since most of these factors are influenced by the ESA manufacturing process, the immunogenicity of biosimilars could be totally unrelated to the reference product. Even when biosimilars are produced from the same genetic construct, using the same technique, formulation and packaging as the innovator product, there is no guarantee that they are comparable with the reference product. In addition, assessing the immunogenicity of biopharmaceuticals lacks international standardisation. When a biopharmaceutical has unique determinants, antibody assays become highly product specific. Another problem is that quality assurance assays for the immunogenicity of biopharmaceuticals are difficult to establish. A typical example is the immunogenicity profile published in the HX575 European Public Assessment Reports (EPAR), where a transient binding antibody response was seen in a number of intravenously treated renal failure patients in the pivotal trial. The response was noted among patients treated with either the innovator and/or the biosimilar product [4]. That response has never been experienced previously in any of the previous studies involving innovator ESAs [for a full review on biosimilars, please refer to NDT vol. 21, suppl. 5].

### Epoetin Delta

Contrary to currently available Epos, which are produced from Chinese hamster ovary cell line, epoetin delta is produced from a human cell line. Phase III studies have shown that epoetin delta is effective in maintaining Hb values at between 10 and 12 g/dl for up to 24 weeks when administered intravenously three times a week in hemodialysis patients [5], and subcutaneously 1–3 times a week in predialysis patients [6].

### Long-Acting Erythropoiesis-Stimulating Agents

CERA (continuous erythropoietin receptor activator; created by F. Hoffmann-La Roche, Ltd.) is a new long-acting agent with an extended duration of action. Its design is prompted by previous knowledge that modification of proteins with amphiphilic polymers can result in an increased half-life, although the properties may vary with the number and size of the polymer molecules attached [7]. CERA is created by integrating a large polymer chain into the epoetin molecule, thus increasing the molecular weight to twice that of epoetin at approximately 60 kDa. This methoxy-polyethylene glycol polymer chain is integrated via amide bonds between the N-terminal amino group or the e-amino group of lysine (predominantly lysine-52 or lysine-45), using a single succinimidyl buta-
noic acid linker [8]. Polyethylene glycols (PEGs) are a group of water-soluble polymers of varying molecular weights. When linked covalently to proteins, PEGs alter protein properties in ways that extend their potential uses. Changing the size of the polymer could generate different preparations of varying molecular weights and plasma half-lives. Integration of a large polymer into the epoetin molecule could have two important advantages: first, reduction of immunogenicity [9]. In keeping with this is the finding that none of the patients that participated in phase III trials of CERA (n > 2,000) developed anti-Epo or anti-CERA antibodies. The second ad-

### Table 1. Possible future agents in anaemia management

<table>
<thead>
<tr>
<th>Product</th>
<th>Mechanism of action</th>
<th>Route of administration</th>
<th>Development stage</th>
<th>Anticipated marketing authorisation</th>
<th>Potential advantages</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biosimilar epoetins</td>
<td>recombinant human Epo</td>
<td>s.c./i.v.</td>
<td>phase III–IV</td>
<td>2007</td>
<td>? cheaper</td>
<td>quality/ immunogenicity</td>
</tr>
<tr>
<td>Epoetin delta</td>
<td>recombinant human Epo</td>
<td>s.c./i.v.</td>
<td>phase III–IV</td>
<td>2007</td>
<td>? once weekly dosing</td>
<td>no extra advantage over available epoetins</td>
</tr>
<tr>
<td>CERA</td>
<td>Epo-methoxy-polyethylene glycol polymer</td>
<td>i.v./s.c.</td>
<td>phase IV</td>
<td>2007</td>
<td>long-acting: continuous sustained effect</td>
<td>long acting: difficult to terminate effect once administered</td>
</tr>
<tr>
<td>Hematide</td>
<td>Epo mimetic peptide</td>
<td>i.v./s.c.</td>
<td>phase II–III</td>
<td>2010</td>
<td>– long-acting: continuous sustained effect</td>
<td>long acting: difficult to terminate effect once administered</td>
</tr>
<tr>
<td>FG-2216</td>
<td>prolyl hydroxylase inhibitor (HIF stabiliser)</td>
<td>oral</td>
<td>phase II</td>
<td>?</td>
<td>– stimulation of endogenous erythropoietin</td>
<td>? long-term safety</td>
</tr>
<tr>
<td>FG-4592</td>
<td>prolyl hydroxylase inhibitor (HIF stabiliser)</td>
<td>oral</td>
<td>phase II</td>
<td>?</td>
<td>– stimulation of endogenous erythropoietin</td>
<td>? long-term safety</td>
</tr>
<tr>
<td>CTNO 528</td>
<td>Epo mimetic anti-body fusion protein</td>
<td>i.v./s.c.</td>
<td>phase I</td>
<td>?</td>
<td>? usefulness in patients with Epo-induced PRCA</td>
<td>? long-term safety</td>
</tr>
<tr>
<td>Aerosolized Epo</td>
<td>Epo-IgG Fc aerosol</td>
<td>inhalation</td>
<td>phase I</td>
<td>?</td>
<td>easy to deliver</td>
<td>– variable bioavailability</td>
</tr>
<tr>
<td>HCP inhibitors</td>
<td>HCP inhibitors</td>
<td>oral</td>
<td>preclinical</td>
<td>?</td>
<td>? usefulness in Epo hyporesponsiveness</td>
<td>? long-term safety</td>
</tr>
<tr>
<td>K11706</td>
<td>GATA inhibitors</td>
<td>oral</td>
<td>preclinical</td>
<td>?</td>
<td>? usefulness in inflammation/ Epo hyporesponsiveness</td>
<td>? long-term safety</td>
</tr>
<tr>
<td>Oral Epo</td>
<td>(mucoadhesive tablet)</td>
<td>oral/buccal</td>
<td>preclinical</td>
<td>?</td>
<td>easy to deliver</td>
<td>– variable bioavailability</td>
</tr>
<tr>
<td></td>
<td>– plasmid transfer</td>
<td></td>
<td></td>
<td></td>
<td>– long acting; continuous sustained effect</td>
<td></td>
</tr>
<tr>
<td></td>
<td>– hypoxia-dependent AAV gene therapy</td>
<td></td>
<td></td>
<td></td>
<td>– long acting: difficult to terminate effect once administered</td>
<td></td>
</tr>
<tr>
<td></td>
<td>– gene switch</td>
<td></td>
<td></td>
<td></td>
<td>– long acting: difficult to terminate effect once administered</td>
<td></td>
</tr>
<tr>
<td></td>
<td>– antigen-driven B cell-mediated Epo-methoxy-polyethylene glycol polymer</td>
<td></td>
<td></td>
<td></td>
<td>– long acting: difficult to terminate effect once administered</td>
<td></td>
</tr>
</tbody>
</table>


Mikhail/Covic/Goldsmith
vantage of PEGylated Epo is its unique pharmacodynamic properties. Plasmon resonance biosensor (Biacore® Biacore AB, Freiburg, Germany) studies have shown that CERA has a 50-fold lower binding affinity when compared to epoetin beta, but its dissociation rate is much faster. This specific binding constant of CERA permits attachment to the Epo receptor (EPOR) and stimulation of erythropoiesis, followed by rapid dissociation from the receptor rather than internalisation. It also leads to a higher concentration of CERA at the receptor site compared to epoetin [10]. These data suggest that CERA has receptor-binding and pharmacokinetic properties that give rise to a more potent stimulation of erythropoiesis in vivo than epoetin, with regard to both the magnitude and the duration of response [11].

Pharmacokinetic studies have demonstrated a prolonged serum half-life of CERA (mean 134 h for the i.v. route and 139 h for the s.c. route). The clearance of the drug (given via either route) was low and, more importantly, no drug accumulation was observed when a steady state was achieved using different frequencies [12]. A multicenter phase II study assessed the effect of CERA in rHuEpo-naïve patients with CKD but not on dialysis. A dose-dependent, frequency-independent response to CERA treatment was observed. Erythropoietic responses to CERA were sustained until the end of the study (18 weeks) for all the CERA dose groups [13]. Similar observations were obtained in a phase II multicenter study in 61 haemodialysis patients [14].

Phase III clinical trials have shown that CERA once every 2 weeks corrects anaemia in CKD patients who are or are not on dialysis, whereas once-monthly CERA maintains stable haemoglobin levels when patients are directly converted from the more frequent epoetin or darbepoetin-α administration [15, 16]. There has been no evidence of antibody development in any patient treated with CERA so far.

PEGylated products are eliminated, mainly unmetabolised, via the biliary and urinary routes. Toxic doses cause liver and renal damage. Nevertheless, toxicity of PEGylated product is extremely unlikely to develop clinically since exposures from PEGylated proteins are at least 600-fold lower than the toxic dose [17]. Attempts at integrating naturally occurring polymers into Epo molecules could be an attractive alternative to PEGylated Epo. PolyXen, created by Lipoxen and based on polysalic acid, is a naturally occurring polymer which is biodegradable, non-immunogenic and non-toxic. Phase I clinical trials on the PolyXen-Epo complex are currently underway.

**Erythropoietin Mimicry**

Using random phage display libraries and receptor affinity purifications, it was possible to isolate a group of small peptides with no structural homology to the endogenous Epo molecule that act as full agonists of the EPOR [18]. Mimetic polypeptides have a shorter plasma half-life in circulation compared to native proteins. Such a limitation can be overcome by combining the polypeptide to a polymer (e.g. PEG) (fig. 1).

**Hematide**

Hematide (created by Affymax) is synthetic PEGylated peptide-based ESA with a completely novel amino acid
sequence that is totally unrelated to Epo or to any other known naturally occurring human sequences.

Results of a phase I study demonstrated that single intravenous doses (0.025, 0.05, and 0.1 mg/kg) of hematide resulted in dose-dependent increases in circulating reticulocytes in 28 healthy volunteers, with clinically and statistically significant increases in red blood cells from baseline, an effect sustained for at least 4 weeks [19]. A phase II, open-label dose-finding study examined the safety and pharmacodynamics of hematide in ESA-naive CKD patients not on dialysis. Sixty patients with baseline Hb values 9–11 g/dl received a subcutaneous injection of hematide once every 4 weeks for up to 6 doses. The reticulocyte count peaked at about 2 weeks after each injection. Correction of anaemia (Hb >11 g/dl) was achieved in 24 of 30 (80%), and 29 of 30 (97%) patients by 4 and 8 weeks of treatment, respectively. Subsequent doses maintained Hb values in the target range for up to 6 months [20]. Phase III studies are currently underway in the USA and Europe.

Similar to CERA, hematide seems promising and may have several potential advantages over currently available ESAs, including prolonged half-life and pharmacodynamic activity with an expected dosing interval every 3–4 weeks [20]. Hematide, being a peptide-based molecule, may stimulate the production of human anti-hematide antibodies, but such antibodies are unlikely to cross-react with endogenous Epo or any other ESAs, therefore giving them the potential for treatment of patients with pure red cell aplasia.

The pharmacodynamic advantage of longer-acting preparations (hematide and CERA) could also be a potential limitation. The longer elimination half-life could be an important factor in the management of patients with accidental overdose or those developing drug-related side effects. While it is common clinical practice to omit one dose of shorter-acting ESAs in patients developing some drug-related side effects (hypertensive emergencies, abnormally high Hb), it is not clear how such conditions would be managed when longer-acting preparations come into clinical practice.

Non-Peptide Mimetics

Attempts at designing orally active ESAs have led to designing small non-peptide molecules capable of supporting the in vitro proliferation of Epo-responsive cells. Several compounds have been created, but their EPOR affinity and biological activity were much lower than those of native Epo. Although they did not materialise into clinical application, such findings show that small, orally active molecules with interesting potential do exist [21].

Fusion Peptides

A fusion protein, consisting of two complete human Epo domains linked in tandem by a 17-amino acid flexible peptide, showed a high affinity to EPOR and a greatly enhanced in vitro and in vivo activity compared with rHuEpo. It has also been found that the length of the peptide linker separating the two Epo domains could influence the activity of the biological molecule. Increasing the length of the linker resulted in reduction of the activity of the molecule to a level comparable to that of rHu-Epo [22].

Since GM-CSF is required for early erythropoiesis prior to the expression of EPOR (stimulation of the burst-forming unit erythroid, BFU-e), another dimeric fusion protein composed of a GM-CSF-Epo complex was capable of inducing erythropoiesis in cynomolgus monkeys [23]. Unfortunately, that molecule was later found to induce anti-Epo antibodies and severe anaemia as well [24].

CTNO 528

One strategy to increase a therapeutic protein half-life is to modify the fate of proteins within the target cell. The fusion of therapeutic proteins to albumin or the Fc region of an antibody, in addition to increasing the effective molecular weight of the protein, promotes recycling out of the cell upon endocytosis via the Fc and albumin recycling receptors, so these strategies are particularly useful for enhancing the serum half-life of therapeutic proteins [25, 26].

CTNO 528 (Centocor) is an erythropoiesis mimetic antibody fusion protein with no structural similarity to rHuEpo. Rats treated with a single subcutaneous dose of CTNO 528 showed a longer-lasting reticulocytosis and Hb rise compared with treatment with rHuEpo or darbepoetin. CTNO 528 was also effective in correcting anaemia in rat models of pure red cell aplasia [27]. A phase I study in healthy males showed that a single intravenous dose of CTNO 528 produced a dose-dependent increase in reticulocyte count and in Hb concentration (maximum effect days 8 and 22, respectively). In addition, there was a dose-dependent increase in soluble transferrin receptor and endogenous Epo levels (the latter is probably due to competitive EPOR binding). None of the 24 treated subjects developed antibodies to CTNO 528 [28].
Increasing Epo Gene Expression

An exciting tool to treat anaemia of chronic disease could be by simply increasing Epo expression. In persons with normal renal function, plasma Epo levels are inversely proportional to Hb concentrations. Several regulatory DNA sequences and transcription factors act as modulators of the Epo gene expression, e.g. the hypoxia response element HRE, the GATA family, and HCP (SHP-1) inhibition.

Epo gene expression is stimulated by a decrease in arterial oxygen tension (e.g. high altitudes) or when oxygen affinity of the blood increases. The key regulatory DNA sequence that acts as an oxygen sensor is HRE, composed of nucleotide sequences to which HIF (a heterodimer composed of two subunits, α and β) can bind. Both HIF-1α and HIF-1β are continuously being produced. HIF-1β is protected from degradation by cytoplasmic proteolytic enzymes by its sequestration within the nucleus. Under normoxia, HIF-1α is hydroxylated by cytoplasmic proline hydroxylase (PH), which requires iron and 2-oxoglutarate for its action. Prolyl hydroxylated HIF-1α is recognised and tagged with the von Hippel-Lindau gene product (pVHL). The HIF-1α/pVHL product forms a complex with E3 polyubiquitin. The resulting polyubiquitinated HIF-1α is subsequently hydrolysed by proteosomes.

Under hypoxic conditions, PH is inactivated, and, subsequently, HIF-1α is protected from degradation and is enabled to enter the nucleus to form a heterodimer with the nuclear HIF-1β, resulting in gene transcription.

Genetic mutation in the HIF-1α regulatory pathway could result in congenital polycythaemia. A typical example is seen in patients with Chuvash syndrome, a disorder characterised by a homozygous mutation (598C>T) of the VHL gene [32]. Although endemic to the Chuvash population of Russia, this mutation occurs worldwide.
and originates from a single ancient genetic event [33]. In that condition, as a result of mutation of the VHL gene, pVHL is defective and as a result, the HIF-1α level is elevated under normoxic conditions leading to congenital polycythaemia in those affected (fig. 2c). In a matched cohort retrospective mortality and cross-sectional morbidity study, involving 96 patients with Chuvash polycythaemia, VHL 598C>T homozygosity was associated with vertebral hemangiomas, varicose veins, lower blood pressures, and elevated serum VEGF concentrations, as well as premature mortality related to cerebral vascular events and peripheral thrombosis. While the Hb-adjusted serum Epo concentrations are approximately 10-fold higher in those affected than in healthy controls, their Epo response to hypoxia remains unaffected [34]. Spino-cerebellar haemangioblastomas, renal carcinomas, and pheochromocytomas typical of classical VHL syndrome were not found. These data suggest that overexpression of HIF-1α and VEGF in Chuvash polycythaemia is not sufficient to cause the tumorigenesis observed in patients with the classical VHL syndrome, since the VHL protein has some other yet unidentified substrates than HIF, that may have roles in the growth and behaviour of cells [35, 36].

Prolyl Hydroxylase Inhibitors (PHIs)

Several orally active PHIs are being developed and are under clinical trials by FibroGen. A small phase II clinical trial has shown that one PHI, FG-2216, given orally twice a week, corrects anaemia in ESA-naïve CKD patients, and maintains the Hb level in those treated previously with Epo. These results suggest that CKD patients can produce Epo in response to PHI despite renal damage and fibrosis. The circulating levels of endogenous Epo induced by PHIs were much lower than the levels report-ed in patients treated with ESAs [37]. In addition, these preparations may improve erythropoiesis by modulating iron metabolism. In one study involving another PHI (FG-4592), treatment was reported to dramatically reduce abnormally high levels of hepcidin back to normal and restore the natural balance in iron regulation in an experimental model of inflammation-induced anaemia [38]. The downregulation of hepcidin by PHI prevents ferroportin degradation and leads to the improvement of iron mobilization from storage sites for bone marrow util-ization.

Although PH inhibition could stabilize not only HIF-1α but a host of other proteins as well, it is possible that such a potential will not have a clinically significant effect in patients receiving long-term therapy with PHIs, since the stabilization of HIF by PHIs is similar to that observed in patients with Chuvash syndrome (fig. 2d). Nevertheless, multicentre studies are necessary to investigate the safety of PHIs in clinical practice.

GATA Transcription Factors

The GATA family consists of six transcription factors, GATA1–6. They are categorised as a family due to the fact that they all bind to the DNA consensus sequence (A/T)GATA(A/G) by two characteristic zinc-finger motifs specific to the GATA family [39]. The GATA family is divided into two subfamilies on the basis of their expression profiles. GATA1–3 belong to the haematopoietic subfamily [40]. GATA-2 is expressed prior to the formation of the blood islands of the mammalian yolk sac and plays a role in the maintenance of the pluripotent stem cells of the haematopoietic system [41]. GATA-2 inhibits Epo gene transcription by binding to the GATA sequence on the Epo promoter, thereby leading to the downregulation of Epo mRNA expression, and subsequent Epo synthesis, in response to hypoxia [42]. GATA-2 therefore acts as a negative regulatory molecule of Epo gene expression. L-NMMA, a candidate suppressor of Epo expression in patients with CKD [43], is known to reduce Epo production in vitro by increasing GATA-2 DNA binding [44]. Other factors that could exert a negative tropic action on the Epo gene via increasing GATA-2 expression include TNF-α and NFκB. Disrupting the negative signal could prove a beneficial future tool in the management of renal anaemia. K-11706, a GATA-2-spe-cific inhibitor, improved Epo production following inhibition by IL1-β or TNF-α in Hep3B cells in vitro and in an in vivo mouse assay. Oral administration of K-11706 reversed the decreases in Hb and serum Epo concentra-tions, reticulocyte counts, and numbers of erythroid colony-forming units (CFU-Es) induced by IL1-β or TNF-α [45]. These results raise the possibility of using orally ad-ministered K-11706 as an Epo supplement for treating pa-tients with renal anaemia.

HCP (SHP-1) Inhibition

rHuEpo hypo-responsiveness could be due to the altered gene expression profile of Epo signal transduction molecules. Recently, the role of the src homology domain 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1) in the pathogenesis of rHuEpo hypo-responsiveness has re-ceived significant attention. SHP-1, also known as haematopoietic cell phosphatase (HCP), is a protein tyrosine phosphatase located in the cytoplasm of hematopoietic cells and was originally identified in human breast carci-
SHP-1 binds to the negative regulatory domain of EPOR via its src homology 2 domains and causes dephosphorylation of JAK2, thus functioning as a negative regulator of intracellular signal transduction [47]. In one study, the expression of SHP-1 by CFU-E was found to be diminished in 60% of the patients with polycythaemia vera [48]. In another study, mRNA and protein expression and tyrosine phosphorylation of SHP-1 was significantly increased in CD34+ cells derived from rHuEpo hypo-responsive haemodialysis patients compared with the rHuEpo-responsive group. In addition, the treatment of CD34+ cells from rHuEpo-hyproresponsive patients with SHP-1 antisense oligodeoxynucleotide decreased SHP-1 protein expression and upregulated STATS5, and resulted in the partial recovery of BFU-E colony formation [49]. The gene for SHP-1 has been cloned and SHP-1 inhibitors have been identified. In vitro inhibition of SHP-1 resulted in a dose-dependent erythroid proliferation [50]. Targeting SHP-1 activity in a certain group of CKD patients could be a novel method beneficial in both improving responsiveness and reducing rHuEpo requirements.

**Gene Therapy**

A variety of methods have been reported for experimental gene therapy. The use of Epo-secreting genetically modified fibroblasts resulted in Hb normalisation in Epo-deficient mice [51]. Another method could be the injection of a plasmid-encoded Epo gene into the skeletal muscle followed by electroporation (EP, gene incorporation into nuclear DNA using an intensified electric current) [52]. This method was successful in treating experimental renal anaemia in uraemic rats [53]. Epo gene transfer, using an adenovirus-associated vector (AAV), into the skeletal muscle of rats also resulted in long-term Epo expression in mice with polycystic kidney disease [54].

A hypoxia-dependent gene therapy with an AAV-carrying Epo gene, driven by HRE, has been tested in vivo. Injection of hypoxia-dependent Epo-associated AAV into hind-limb skeletal muscles of Epo-deficient mice resulted in an increase in haematocrit from 20 to 50%. Interestingly, the haematocrit level stabilised without overshooting the normal ranges. That was because the promoter was switched off by the oxygenation of peripheral blood [55]. This finding could have important clinical relevance as normalisation of Hb without running any risk of developing secondary polycythaemia, with its possible potential serious complications, is an ideal characteristic of CKD patients.

Mifepristone (an antiprogestin) was also used in Epo gene therapy in experimental animals. Nordstrom [56] designed a plasmid-based, muscle-specific ‘Gene Switch’ system that was delivered to skeletal muscle by EP and provided regulated Epo expression in mice and rats in a manner that was only dependent on orally administered mifepristone. Erythropoiesis was induced (switched on) with the oral administration of a small amount of mifepristone, and after achieving the desired haematopoietic response, Epo gene expression was terminated (switched off) by withholding oral mifepristone. Regulation was effective with low doses of mifepristone and provided regulated haematocrit changes for more than 6 months.

Takács et al. [57] made use of the ability of antigen-specific lymphocytes to undergo repeated cycles of antigen-driven clonal expansion and contraction as an elaborate tool for Epo gene delivery. They introduced genes encoding Epo into a small number of antigen-specific B lymphocytes of transgenic mice. The mice were then immunised with a specific antigen, phycoerythrin, giving rise to a pool of B cells that would proliferate and express Epo when stimulated by exposure to phycoerythrin. The mice were subsequently sacrificed, and lymphocytes were harvested from their spleen and lymph nodes and injected into mice with anaemia due to Epo deficiency. Serum Epo levels and haematocrit values increased in the recipient mice in response to the administration of phycoerythrin, and the time course of this response was consistent with the known kinetics of the clonal expansion of B cells in response to an antigen. Furthermore, the effect was maintained during several cycles of antigen challenge.

**Stimulating Erythropoiesis by Non-Epo-Related Mechanisms: PBI-1402**

PBI-1402 (created by ProMetic) is a synthetic molecule with oral bioavailability. Preclinical studies demonstrated a haematopoietic progenitor stimulator effect. Phase I trials demonstrated an efficacy comparable with Epo, G-CSF and GM-CSF, and an additive effect was observed in combination with Epo, G-CSF or GM-CSF in vitro. Since PBI-1402 exerts its activity via a different mechanism(s) of action than Epo, it needs baseline endogenous Epo production to exert its effect. Therefore, it may be used as an adjuvant therapy to ESAs. Trials to assess its efficacy in treating patients with chemotherapy-induced anaemia and MDS will commence in the near future. Neverthe-
less, preclinical studies also showed that it can correct anaemia in experimental rat models of chronic renal failure.

**Modifying the Route of Epo Delivery**

*Aerosolised Erythropoietin*

With the successful introduction of inhaled insulin (exubera) into clinical practice, attention will eventually be focused on the development of an inhalation form of Epo. Such attempts date back a few years when a naturally occurring receptor-mediated transport pathway to deliver large therapeutic proteins non-invasively was tested to assess its efficacy in delivering Epo. The normal function of the receptor, known as the neonatal Fc receptor or FcRn, is to transport immunoglobulins across cells and to protect circulating immunoglobulin from degradation. In rodents, after weaning, the expression of FcRn drops precipitously and its level remains relatively low in adult rodent epithelial tissues. In humans, unlike rodents, FcRn expression remains high in certain adult tissues, specifically in epithelial cells lining the lung, kidney and intestine. Its expression in lung tissue is mainly in the central airways with very little expression in alveoli of both non-human primates and humans [58]. Dumont et al. [59] designed a molecule comprised of full-length human Epo fused recombinantly to the Fc portion of human IgG1. Using three different doses in healthy male volunteers (3, 10 and 30 μg/kg), the investigators showed dose-dependent concentrations of Fc-rHuEpo in the serum while an increase in circulating reticulocytes was only evident in the highest-dose group. This pathway could potentially be a feasible approach to drug delivery rather than using the parenteral route. The usefulness of such a method in treating anaemia of CKD has yet to be evaluated.

*Oral Erythropoietin*

The oral delivery of rHuEpo was also assessed in animals. In one study, mucoadhesive tablets containing Epo and an absorption enhancer (Labrasol) for oral administration were studied in rats and dogs [60]. Mucoadhesive tablets were covered with a water-insoluble backing layer and a pH-sensitive covering layer (increases drug permeability upon contact with intestinal secretion). Theoretically, the preparation is designed to allow for the tablet to reach the small intestine intact. In one study, intrajejunal administration of a single tablet containing 100 IU/kg rHuEpo to beagle dogs showed a maximum drug concentration of 24.6 ± 4.1 mIU/ml. A corresponding increase in reticulocyte percentage was noted 8 days after oral administration. The oral bioavailability of rHuEpo was comparable to that of the intravenous route [60]. However, the authors did not explain how an orally administered mucoadhesive rHuEpo preparation could bypass hepatic metabolism and achieve adequate plasma levels. Such a method has not yet been assessed in humans.

**Non-Erythropoietic Properties of ESAs**

*Ischaemia-Reperfusion Injury*

In addition to modulating erythropoiesis, Epo expressed in response to hypoxia can exert an anti-apoptotic effect that can protect different organs against hypoxia-induced tissue injury. The EPOR is now known to be expressed by non-erythropoietic tissues such as neurons, astrocytes, cardiomyocytes, endothelial cells, hepatocytes and mesangial cells, to name but a few. But by far the most extensively investigated system with regard to the cytoprotective effects of rHuEpo is the nervous system. Multiple studies on models of hypoxic injury have shown that whereas Epo and EPOR are expressed in a highly restricted manner under normal brain conditions, the expression of both proteins is markedly upregulated following ischaemic and other stressor insults [61]. These findings have sparked significant enthusiasm for further investigations. Furthermore, the desire to develop a cytoprotective agent that is effective and safe has prompted attempts at designing a rHuEpo analogue that retains its anti-apoptotic/cytoprotective effect(s) but lacks its erythropoiesis-modulating effect. Creating an ultra-short-acting rHuEpo molecule could achieve cytoprotection without significantly affecting erythropoiesis. AsialoEpo, generated by total enzymatic desialylation of rHuEpo, possesses a very short plasma half-life (10 min after i.v., 2.5 h after s.c. administration) and was found to be fully neuroprotective in three different models of ischaemic-traumatic neuronal injury [62]. Another strategy to achieve silencing erythropoiesis is carbamylation of lysines in the Epo molecule. CEpo, produced by converting all lysines in Epo molecules to homocitrulline by carbamylation [63], has been found to be cytoprotective in vitro and conferred neuroprotection against experimental models of stroke, spinal cord compression, diabetic neuropathy and experimental autoimmune encephalomyelitis at a potency and efficacy comparable to rHuEpo [63]. Also, very promising results from various animal models are increasingly suggesting a possible very relevant car-
dioprotective and nephroprotective role for ESAs, particularly for preventing/reversal of ischaemia-reperfusion injury lesions (for a comprehensive review, see Maiese et al. [64]).

It is likely that over the next decade, the cytoprotective use of rHuEpo or its analogues will come into clinical practice. At the time of submitting the manuscript for publication, of more than 45 clinical trials on rHuEpo registered with the National Institute of Health, there are more than 10 trials designed to assess the potential cytoprotective benefits of rHuEpo in various clinical settings of tissue hypoxia/injury (table 2).

### ESA and Cancer

Expression of Epo and EPORs has been demonstrated in a variety of human cancers [65]. The Epo stimulation of cancer cells in vitro activates signal transduction pathways, including phosphatidylinositol 3-kinase-Akt and JAK-STAT [66]. Depending on the type of cancer, activation of the Epo/EPOR signalling axis results in measurable cellular effects, including proliferation, anti-apoptosis, and invasion [67–69]. In a recent overview that evaluated survival in 13,611 patients with cancer who were treated in 51 phase III trials, and venous thromboembolism (VTE) among 8,172 patients with cancer who were treated in 38 phase III trials, compared to no treatment, treatment with ESA was associated with a 1.57-fold increased VTE risk and a 1.10-fold increased mortality risk [70]. Recently, following the reporting of two further trials (one in patients with primary breast cancer receiving chemotherapy prior to surgery and the second in patients with cervical cancer treated with chemotherapy and radiation) showing increased mortality in the ESA-treated arms, the FDA strengthened its warning regarding the use of ESA in patients with cancer, restricting its use to cancer patients who develop chemotherapy-induced anaemia [71].

### ESA: Drug Interactions

With the increased use of ESA in the treatment of anaemic patients with advanced heart failure, the effect of ESA is likely to be influenced by other concomitant medications. ACEI (angiotensin enzyme inhibitor) or angiotensin II (AII) receptor blocker therapy, especially at high doses, may increase the Epo requirement in dialysis patients [72]. Possible mechanisms to account for this effect include loss of AII-induced Epo release, reduction in the sensitivity to Epo, and an increase in plasma levels of the tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline, which prevents the recruitment of pluripotent hematopoietic stem cells and normal early progenitors into the S-phase of the cellular cycle by maintaining them in the Go phase [73]. Anaemic patients requiring either ACEI or AII blocker therapy may require a different approach to anaemia management to optimise their response to ESA therapy.

### Conclusions

Although currently available ESAs are effective in the management of CKD patients with anaemia, there are several important limitations to their effective and widespread use. There is thus still a great need for progress in this area with further drug development. While gene therapy remains in the early phases of development, third-generation agents (CERA and hematide) could simplify anaemia management and improve patient compliance relatively soon. Orally active preparations could also provide an attractive alternative/supplement to currently available agents.

It is clear that the field of renal anaemia and its treatment has come of age, but a new much more exciting and potentially useful set of agents is about to present itself to physicians and patients. If successful, with the introduction of potentially less expensive, more practical therapies, it might be possible to entertain much more widespread therapy for anaemia involving many more clinical

<table>
<thead>
<tr>
<th>Condition</th>
<th>Drug tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trauma-induced critical illness</td>
<td>epoetin α</td>
</tr>
<tr>
<td>Chemotherapy-induced peripheral</td>
<td>epoetin α</td>
</tr>
<tr>
<td>neuropathy in patients with ovarian cancer</td>
<td>epoetin α</td>
</tr>
<tr>
<td>Chronic stroke; amyotrophic lateral sclerosis</td>
<td>epoetin α</td>
</tr>
<tr>
<td>Subarachnoid haemorrhage</td>
<td>epoetin β</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>epoetin β</td>
</tr>
<tr>
<td>Cardiopulmonary bypass</td>
<td>epoetin α</td>
</tr>
<tr>
<td>Malignant spinal cord compression</td>
<td>epoetin α</td>
</tr>
<tr>
<td>Renal transplant recipients from non-heart-beating donors</td>
<td>epoetin β</td>
</tr>
<tr>
<td>Traumatic brain injury</td>
<td>epoetin α</td>
</tr>
<tr>
<td>Sepsis</td>
<td>epoetin α</td>
</tr>
<tr>
<td>Scuba divers</td>
<td>epoetin α</td>
</tr>
<tr>
<td>Friedreich’s ataxia</td>
<td>epoetin α</td>
</tr>
<tr>
<td>HIV-associated neuropathy</td>
<td>epoetin α</td>
</tr>
<tr>
<td>Paediatric cardiac surgery</td>
<td>epoetin α</td>
</tr>
</tbody>
</table>

Table 2. Some of the registered multicenter trials testing non-erythropoietic effects of rHuEpo
settings. However, given that we have several agents that mimic human Epo and its interaction with the cell surface receptor, and that we have clear proof of efficacy, and a well-understood side effect profile derived from nearly two decades of clinical use, providing sufficient safety and outcome data for any of the non-EPO-based ESA therapies would be a challenging but very necessary hurdle before we could consider adopting a novel strategy. Even in 2008, despite two full decades of clinical use, we can get major surprises, for example, two recently published trials have examined whether full Hb correction, compared with standard target Hb values, may improve cardiovascular morbidity [74] and mortality [75] in CKD patients. Both studies were negative – indeed one suggested that in attempting to achieve a higher target (13.5 g/dl) there may be an increased development of adverse cardiovascular events. Despite the limitations of both studies [76], they both highlight an important fact – we still do not know enough about the remarkable compound Epo. Anaemia treatment paradigms are set to change in challenging and beneficial ways; the field is vibrant with manifold opportunities for better correction of anaemia and thereby, we hope, better health for many more patients.

References


Stimulating Erythropoiesis


